LegoChem Biosciences Inc (141080) — Cash Flow-to-Debt Ratio
LegoChem Biosciences Inc (141080) has a Cash Flow-to-Debt Ratio of -0.09x as of September 2025, meaning its operating cash flow of ₩-12.15 Billion could theoretically repay 0% of its total liabilities (₩136.37 Billion) in one year. See free cash flow generation of LegoChem Biosciences Inc to measure how efficiently the company converts operating cash flow to free cash.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
LegoChem Biosciences Inc Cash Flow-to-Debt Ratio (2014–2024)
Historical debt coverage capacity for LegoChem Biosciences Inc across 11 annual periods. Also explore LegoChem Biosciences Inc (141080) equity growth momentum to track the company's year-over-year net asset growth rate.
Annual Cash Flow-to-Debt Ratio for LegoChem Biosciences Inc (2014–2024)
Year-by-year debt coverage analysis for LegoChem Biosciences Inc. For market capitalisation and broader financial context, see 141080 stock market capitalisation.
| Year | CF-to-Debt Ratio | Operating CF (KRW) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2024 | 0.64x | ₩78.48 Billion | ₩122.38 Billion | ▲ +142.5% |
| 2023 | -1.51x | ₩-62.24 Billion | ₩41.28 Billion | ▼ -595.8% |
| 2022 | -0.22x | ₩-7.14 Billion | ₩32.93 Billion | ▲ +82.2% |
| 2021 | -1.22x | ₩-42.05 Billion | ₩34.46 Billion | ▼ -94.9% |
| 2020 | -0.63x | ₩-14.89 Billion | ₩23.79 Billion | ▼ -172.0% |
| 2019 | 0.87x | ₩24.11 Billion | ₩27.73 Billion | ▲ +236.5% |
| 2018 | -0.64x | ₩-12.76 Billion | ₩20.02 Billion | ▼ -164.0% |
| 2017 | -0.24x | ₩-8.21 Billion | ₩34.03 Billion | ▲ +45.4% |
| 2016 | -0.44x | ₩-13.04 Billion | ₩29.49 Billion | ▼ -30.7% |
| 2015 | -0.34x | ₩-8.54 Billion | ₩25.26 Billion | ▲ +41.2% |
| 2014 | -0.57x | ₩-7.88 Billion | ₩13.71 Billion | — |